Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
AR-9281 inhibits soluble epoxide hydrolase.
- Mechanism
- Curator reviewed
AR9281 inhibits soluble epoxide hydrolase (s-EH), an enzyme that plays a key role in the cytochrome P450 pathway of arachidonic acid metabolism. Nuclear factor alpha B (NF-alphaB) is a transcription factor implicated in cardiac hypertrophy, and can be anti or pro apoptotic under different conditions. Epoxyeicosatrienoic acids (EETs), a product of cytochrome P450 epoxygenase enzyme action, have a variety of anti-hypertensive and anti-inflammatory effects. EETs have a vasodilatory action similar to endothelium derived hyperpolarizing factor and may inhibit NF-alphaB through a currently unknown mechanism. The enzyme s-EH catalyzes the breakdown of EETs to dihydroxyeicosatrienoic acids. AR9281's inhibition of s-EH enhances EETs anti-hypertensive and anti-inflammatory activities by preventing their breakdown by s-EH, as well as inhibiting NF-alphaB.
- Primary indication
- Investigated for use/treatment in hypertension.Curator reviewed
- Formula / weight
- C18H29N3O2 · 319.449 g/mol (avg)
- Also known as
- APAU
- Code names
- AR-9281
Resolves to
HUDQLWBKJOMXSZ-UHFFFAOYSA-NSMILESCC(=O)N1CCC(CC1)NC(=O)NC12CC3CC(CC(C3)C1)C2What you can answer from here — as of August 26, 2024
Which drugs share a target with AR-9281, and which of those have an active Phase 3 trial?